Скачать или смотреть Incentives to Stimulate Innovation in Antimicrobial Development

Highlights from “Antifungus Among Us: Recognizing Vulnerability and Opportunity with the Next-Generation of Antifungals” panel at the 2017 BIO International Convention. Dr. Jeffrey Stein, Chairman of the AWG, joined fellow AWG members Dr. Marco Taglietti and Dr. Robert Schotzinger, along with other key opinion leaders, to discuss current antimicrobial market failures and potential incentives that could help stimulate much needed innovation in antimicrobial development.

Panel Details:
Antifungus Among Us: Recognizing Vulnerability and Opportunity with the Next-Generation of Antifungals
June 20, 2017 – BIO International Convention

Jeffrey Stein, Ph.D., President and Chief Executive Officer, Cidara Therapeutics
Marco Taglietti, M.D., President and Chief Executive Officer, SCYNEXIS
Robert Schotzinger, M.D., Ph.D., President and Chief Executive Officer, Viamet Pharmaceuticals
Tom Chiller, M.D., M.P.H., Chief, Mycotic Diseases Branch, Centers for Disease Control and Prevention (CDC)
Tim Cooke, Ph.D., Chief Executive Officer, Novadigm Therapeutics
Luke Timmerman, Founder and Editor, The Timmerman Report